Z 13752A

Drug Profile

Z 13752A

Alternative Names: GW 660511X

Latest Information Update: 05 Nov 2002

Price : $50

At a glance

  • Originator Zambon Group SpA
  • Developer GlaxoSmithKline
  • Class
  • Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 05 Nov 2002 Discontinued - Phase-II for Hypertension in United Kingdom (unspecified route)
  • 30 Apr 2002 Phase-II clinical trials in Hypertension in United Kingdom (unspecified route)
  • 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top